

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878


<p>Bombay Stock Exchange Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p>
<p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: February 5, 2016</p>	
<p>Re.: Press Release</p>	

Dear Sir / Madam,

We are forwarding herewith a copy of press release proposed to be published in the newspapers in the matter of un-audited financial results for the quarter / nine months ended on December 31, 2015, the same may please receive in order.

Thanking you,

Yours faithfully,
FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus Cadila's Net Profit up by 38% in Q3

Ahmedabad, February 5, 2016

For the third quarter ended 31st December 2015, Zydus Cadila reported Total Operating Income of Rs. 2428 crores, up by 10% from Rs. 2205 crores in the corresponding quarter of the previous year on a consolidated basis. Net Profit for the same period was up by 38% from Rs. 282 crores to Rs. 390 crores.

During the quarter, the company's business in the US posted sales of Rs. 1072 crores registering a growth of 20%. The company filed 20 ANDAs with the US FDA during the quarter.

In the India formulations market, the company launched 12 new products, including line extensions, of which 1 product was the first to be launched in India. During the quarter, the company launched Tenglyn (Teneligliptin 20mg tablets), the most affordable gliptin for diabetics in India. Tenglyn is priced at just Rs. 7 per tablet which is almost 1/6th the price at which the Gliptins were initially launched in India.

In Brazil, the company received the regulatory approval for 2 products during the quarter.

During the quarter, the group also received approval from the USFDA to initiate a Phase 2 clinical trial of Saroglitazar in patients with severe hypertriglyceridemia (TG > 500 mg/dL). Lipaglyn™ (Saroglitazar), the group's own patented NCE is currently approved in India as a prescription medicine for the treatment of Hypertriglyceridemia and Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins.
